Drug intelligence / Profile preview

betamethasone + loratadine

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

**betamethasone + loratadine** is a combination drug consisting of two active pharmaceutical ingredients: betamethasone, a synthetic glucocorticoid corticosteroid, and loratadine, a non-sedating antihistamine. The drug is primarily used as an oral solution for the short-term treatment of severe perennial allergic rhinitis and acute exacerbations of allergic rhinitis, especially in pediatric patients. Betamethasone provides potent anti-inflammatory effects by inhibiting pro-inflammatory mediators and suppressing immune responses; loratadine acts as a selective antagonist of the Histamine H1 receptor, reducing symptoms like sneezing, nasal congestion, and pruritus. Clinical studies have demonstrated superior efficacy of the combination over monotherapy for acute allergic symptoms, with good safety for short-term use.

Brand names
Claricort
Other names
loratadine and betamethasone combination
02

Targets

GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)SLC6 (SLC6 family)

Beyond the preview

Go deeper on betamethasone + loratadine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on betamethasone + loratadine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call